Skip to content

Released Aug 3, 2012, after the close

10-Q filed Aug 3, 2012, 34 days after period end · 0001144204-12-042862

Q2 2012 · 10-Q
Revenue$26.11M+3,317.9% vs Q2 2011+576.3% vs Q1 2012
Net Income$9.64MN/M vs Q2 2011N/M vs Q1 2012
EPS Diluted$0.10N/M vs Q2 2011+42.9% vs Q1 2012
Gross Profit$21,979,000N/M
Operating Income$9,620,000N/M
Operating Cash Flowderived$13,124,000N/M
Free Cash Flowderived$12,887,000N/M
Margins · derived
Gross margin84.2%+705.9 pt vs Q2 2011
Operating margin36.8%+1852.0 pt vs Q2 2011
Net margin36.9%+1828.7 pt vs Q2 2011

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2012Q2 2011Q2 2010
Revenue$26.11M$764.00K$1.14M
Net Income$9.64M-$13.69M-$10.04M
EPS Diluted$0.10-$0.16$0.12

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR